Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief

References

• Burger H, Archer D, Barlow D, et al. Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2004; 7: 210–216
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Coope J, Marsh J. Can we improve compliance with long-term HRT?. Maturitas 1992; 15: 151–158
   PubMed Web of Science ®Google Scholar
• Hammond C B. Women's concerns with hormone replacement therapy – compliance issues. Fertil Steril 1994; 62: 1578–60S
   Google Scholar
• Utian W H, Schiff I. NAMS-Gallup survey on women's knowledge, information, sources and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39–48
   Web of Science ®Google Scholar
• Ryan P J, Harrison R, Blake G M, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992; 99: 325–328
   PubMedGoogle Scholar
• Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogen. Lancet 1996; 348: 981–983
   PubMed Web of Science ®Google Scholar
• Goldstein F, Manson J A, Colditz G A, Willett W C, Speizer F E, Stampfer M J. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941
   PubMed Web of Science ®Google Scholar
• Stadberg E, Mattsson L A, Uvebrant M. 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996; 23: 31–39
   PubMed Web of Science ®Google Scholar
• Commission on Human Medicines. Current Problems in Pharmacovigilance 2006; 31: 9–10, Available at: http://www.mhra.gov.uk/mhra/CurrentProblemsInPharmacovigilance. Accessed September 2006
   Google Scholar
• US Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/estrogens progestins/default.htm. Accessed September 2006
   Google Scholar
• The British Menopause Society. Consensus Statement on Hormone Replacement Therapy. Available at: http://www.the-bms.org/consensus.htm. Accessed October 12, 2005
   Google Scholar
• EMEA Public Statement on Recent Publications Regarding Hormone Replacement Therapy. Available at: http://www.emea.eu.int/pdfs/human/press/pus/3306503en.pdf. Accessed: October 13, 2005
   Google Scholar
• Notelovitz M, Lenihan J P, McDermott M, Kerber I J, Nanavati N, Arce J-C. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95: 726–731
   PubMed Web of Science ®Google Scholar
• Greene J G. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31
   PubMed Web of Science ®Google Scholar
• Archer D F. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999; 94: 323–329
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Guidance for industry: Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendations for clinical evaluation. Jan 2003.
   Google Scholar
• Davilla G, Singh A, Karapanagiotou I, et al. Are women with urogenital atrophy symptomatic?. Am J Obstet Gynecol 2003; 188: 382–388
   PubMed Web of Science ®Google Scholar
• Utian W H, Burry K A, Archer D F, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 1999; 181: 71–79
   PubMed Web of Science ®Google Scholar
• Speroff L, Whitcomb R W, Kempfert N J, Boyd R A, Paulissen J B, Rowan J P. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996; 88: 587–592
   PubMed Web of Science ®Google Scholar
• McNagny S E. Prescribing hormone replacement therapy for menopausal symptoms. Arch Int Med 1999; 131: 605–616
   Web of Science ®Google Scholar
• MacLennan A, Broadbent J, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004, Issue 4, Art. No CD002978
   PubMedGoogle Scholar
• Pickar J H, Yeh I T, Wheeler J E, Cunnane M F, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003; 80: 1234–1240
   PubMed Web of Science ®Google Scholar
• Ng C Y, Cloke B, Panay N. Low dose hormone replacement therapy and phytoestrogens. The Year In Gynaecology, J Barter, N Hampton. Clinical Publishing Services, Oxford 2001; 193–214
   Google Scholar
• Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1079
   PubMed Web of Science ®Google Scholar
• Panay N, Toth K, Pelissier C, Studd J. Dose ranging studies of a novel intranasal estrogen replacement therapy. Maturitas 2001; 38(Suppl 1)S15–22
   PubMedGoogle Scholar
• Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44: 157–163
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 2005; 50: 91–97
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Arce J C, Nanavati N, Huang W C. Norethisterone acetate at 0.5 mg dose adds to the efficacy of 1 mg 17β-estradiol on vasomotor symptom relief. Poster presented at Annual Meeting of the North American Menopause Society, TorontoCanada, September, 1998
   Google Scholar
• Paterson M EL. A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982; 89: 464–472
   PubMedGoogle Scholar
• Panay N, Studd J WW. Progestogen intolerance and compliance with hormone replacement therapy. Hum Reprod Update 1997; 3: 159–171
   PubMed Web of Science ®Google Scholar